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Background
Cardiac atrial natriuretic peptide (ANP) regulates arterial
blood pressure, moderates cardiomyocyte growth, and
stimulates angiogenesis and metabolism. ANP binds to
the transmembrane guanylyl cyclase (GC) receptor, GC-
A to exert its diverse functions. This involves a cGMP-
dependent signaling pathwayp r e v e n t i n gp a t h o l o g i c a l
[Ca
2+]i raises in myocytes. In chronic cardiac hypertro-
phy, however, ANP levels are markedly increased and
GC-A/cGMP responses to ANP are blunted due to
receptor desensitization.
Results
Here we show that in this situation ANP binding to GC-A
stimulates a novel cGMP-independent signaling pathway
in cardiac myocytes, resulting in pathologically elevated
intracellular Ca
2+ levels ([Ca
2+
i]). This pathway involves
the activation of TRPC3/C6 Ca
2+ channels (transient
receptor potential canonical channel 3/6) by GC-A which
forms a stable complex with TRPC3/C6 channels. Our
results indicate that the resulting TRPC3/C6-mediated
Ca
2+ entry then stimulates Calmodulin Kinase II (CaMKII)
to phosphorylate L-type Ca
2+ channels leading to
increased L-type Ca
2+ channel mediated Ca
2+ current and
a rise in intracellular Ca
2+ levels.
Conclusion
These observations reveal a dual role of the ANP/GC-A
signaling pathway in the regulation of cardiac myocyte
Ca
2+
i-homeostasis. Under physiological conditions, acti-
vation of a cGMP-dependent pathway moderates the
Ca
2+
i-enhancing action of hypertrophic factors such as
Angiotensin II. By contrast, a cGMP-independent path-
way predominates under pathophysiological conditions,
when GC-A is desensitized by high ANP levels. The
concomitant rise in [Ca
2+
i]i sl i k e l yt oi n c r e a s et h ep r o -
pensity to cardiac hypertrophy and arrhythmias.
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